23 January 2024 - This week, we have reviewed the listing of innovative (patent protected) health care technologies in the NZ Pharmaceutical Schedule for a new indication in 2023. The list is underwhelming.

• January - NIL
• February - ustekinumab
• March - NIL
• April - pembrolizumab
• May - NIL
• June - NIL
• July - rituximab (biosimilar)
• August - NIL
• September - NIL
• October - emicizumab, ocrelizumab
• November - NIL
• December - NIL

All up, just four new indications for patent protected medicines.